Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan, is a mucolytic presented as an oral dosage form for oral use. It reduces mucus viscosity and facilitates expectoration in patients with acute or chronic respiratory conditions, and is commonly employed in the management of bronchitis, chronic obstructive pulmonary disease and asthma with mucus hypersecretion.

GNH USA supplies Mucosolvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable global distribution.

Mucosolvan (ambroxol hydrochloride) is used as a mucolytic agent in several respiratory disorders characterized by thickened secretions.

- Acute bronchitis: improves clearance of sputum and eases cough. - Chronic bronchitis: reduces mucus viscosity to aid expectoration. - COPD: assists in mucus clearance and reduces airway obstruction. - Asthma with mucus hypersecretion: helps loosen secretions for better airway patency.

Like all medicines, ambroxol may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset. - Diarrhea: loose stools. - Taste disturbance: bitter or metallic taste. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Allergic reactions: hives, swelling, or anaphylaxis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: abnormal liver function tests.

Before using Mucosolvan, consider the following precautions to ensure safe and effective therapy.

- Pregnancy: consult a healthcare professional before use as safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Renal impairment: dose adjustment may be required in severe kidney disease. - Hepatic disease: monitor liver function in patients with existing liver conditions. - Concomitant medications: inform the prescriber of all current drugs to assess interaction risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Ambroxol may interact with other medicines; awareness of these interactions helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticholinergic agents: may diminish mucolytic effect. - Monoamine oxidase inhibitors (MAOIs): risk of heightened cholinergic side effects.

Moderate Interactions (Monitor Closely): - Bronchodilators (β2‑agonists): may have additive cough‑suppression effect. - Antibiotics (e.g., macrolides): potential for altered metabolism. - Antihistamines: possible increase in sedation. - Alcohol: may exacerbate gastrointestinal irritation.